Eisai and Biogen Present LEQEMBI (Lecanemab) Real-World LEADER Study Data at AAIC 2026 on Tuesday July 14: A Comprehensive Multicenter Retrospective Study of 432 Early Alzheimer's Disease Patients From Diverse US Clinical Settings Who Received at Least Seven LEQEMBI Infusions as of May 2026 Showed 75.9% of Patients Remained Stable and 6.6% Improved Over an Average of 17 Months of Treatment, 87% Chose to Remain on Treatment, and Results Were Consistent Across Sex, Race, Ethnicity, and APOE Genotype
Eisai and Biogen announced Tuesday July 14, 2026 that data from the real-world Lecanemab in Early Alzheimer's Disease (LEADER) Study, presented at AAIC 2026 in London during the Developing Topics Session '#3-33-DEV-A: Lecanemab Three Years Post-Approval: A Comprehensive Multicenter, Real-World, Retrospective Study (LEADER) in Diverse US Clinical Settings,' documented durable clinical outcomes with LEQEMBI in early Alzheimer's disease. The analysis included 432 early Alzheimer's disease patients from diverse US clinical settings who had received at least seven LEQEMBI infusions as of May 2026. Over an average of 17 months of treatment, 75.9% of patients remained clinically stable and 6.6% improved (moving from mild Alzheimer's disease dementia to mild cognitive impairment due to Alzheimer's disease). 87% of patients chose to remain on LEQEMBI treatment. Results were consistent across sex, race, ethnicity, and APOE genotype, supporting long-term benefits of continuous treatment outside of a controlled clinical trial setting.